Observational studyEuropean journal of hospital pharmacy : science and practice2021

Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis.

Belén Rodríguez de Castro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.